- Report
- April 2025
- 175 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Report
- October 2025
- 195 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Report
- January 2025
- 175 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1068EUR$1,200USD£940GBP
€1335EUR$1,500USD£1,175GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €890EUR$1,000USD£783GBP
€1112EUR$1,250USD£979GBP
- Report
- August 2025
- 100 Pages
Global
From €4360EUR$4,900USD£3,838GBP
- Report
- May 2024
- 130 Pages
Global
From €4916EUR$5,524USD£4,327GBP
€5783EUR$6,499USD£5,091GBP
- Report
- May 2023
- 83 Pages
Global
From €3500EUR$4,213USD£3,189GBP
Pancrelipase is a type of gastrointestinal drug used to treat exocrine pancreatic insufficiency (EPI). It is a combination of enzymes that help the body break down and absorb fats, proteins, and carbohydrates. Pancrelipase is used to treat EPI caused by cystic fibrosis, chronic pancreatitis, and other conditions. It is available in both capsule and liquid form. Pancrelipase is also used to treat malabsorption syndrome, a condition in which the body does not absorb enough nutrients from food.
The pancrelipase market is a growing segment of the gastrointestinal drugs market. It is used to treat a variety of conditions, and is available in both capsule and liquid form. The market is expected to grow due to increasing prevalence of EPI and malabsorption syndrome.
Some companies in the pancrelipase market include AbbVie, Allergan, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
